B. Corkery

562 total citations
9 papers, 450 citations indexed

About

B. Corkery is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, B. Corkery has authored 9 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in B. Corkery's work include HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (4 papers). B. Corkery is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Treatment and Pharmacology (4 papers). B. Corkery collaborates with scholars based in Ireland, Australia and United States. B. Corkery's co-authors include John Crown, Norma O’Donovan, Martin Clynes, Michael J. Duffy, Dimitrios Tryfonopoulos, S. Walsh, Denis M. Collins, John P. Pierce, Denis Evoy and Cecily Quinn and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

B. Corkery

8 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Corkery Ireland	5	284	204	141	108	33	9	450
Jinwei Hao Australia	3	197 0.7×	255 1.3×	129 0.9×	92 0.9×	25 0.8×	3	432
A. Mieke Timmermans Netherlands	11	285 1.0×	335 1.6×	241 1.7×	98 0.9×	28 0.8×	15	629
Robert D. Kendig United States	12	276 1.0×	326 1.6×	91 0.6×	58 0.5×	37 1.1×	15	574
Bylgja Hilmarsdóttir Iceland	15	218 0.8×	366 1.8×	228 1.6×	64 0.6×	30 0.9×	24	573
Ilenia Segatto Italy	14	251 0.9×	290 1.4×	198 1.4×	99 0.9×	26 0.8×	23	536
Patricia Villagrasa Spain	10	293 1.0×	398 2.0×	185 1.3×	106 1.0×	33 1.0×	56	631
Aviva P. Ventura United States	6	140 0.5×	342 1.7×	212 1.5×	79 0.7×	24 0.7×	6	504
Marta Giussani Italy	9	200 0.7×	171 0.8×	106 0.8×	65 0.6×	35 1.1×	16	391
Mansour Alsaleem United Kingdom	15	233 0.8×	258 1.3×	191 1.4×	93 0.9×	70 2.1×	32	526
C Mazeau France	8	170 0.6×	230 1.1×	94 0.7×	68 0.6×	35 1.1×	16	399

Countries citing papers authored by B. Corkery

Since Specialization

Citations

This map shows the geographic impact of B. Corkery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Corkery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Corkery more than expected).

Fields of papers citing papers by B. Corkery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Corkery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Corkery. The network helps show where B. Corkery may publish in the future.

Co-authorship network of co-authors of B. Corkery

This figure shows the co-authorship network connecting the top 25 collaborators of B. Corkery. A scholar is included among the top collaborators of B. Corkery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Corkery. B. Corkery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Gaule, Patricia, Nupur Mukherjee, B. Corkery, et al.. (2019). Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells. Cancers. 11(4). 548–548. 19 indexed citations

2.

Gaule, Patricia, et al.. (2015). Abstract P5-05-08: Sensitivity to c-Met inhibition is increased in dasatinib resistant TNBC cells. Cancer Research. 75(9_Supplement). P5–5. 1 indexed citations

3.

Walsh, Naomi, Susan Kennedy, Annemarie Larkin, et al.. (2012). EGFR and HER2 inhibition in pancreatic cancer. Investigational New Drugs. 31(3). 558–566. 23 indexed citations

4.

Tryfonopoulos, Dimitrios, S. Walsh, Denis M. Collins, et al.. (2011). Src: a potential target for the treatment of triple-negative breast cancer. Annals of Oncology. 22(10). 2234–2240. 113 indexed citations

5.

Corkery, B., John Crown, Martin Clynes, & Norma O’Donovan. (2009). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology. 20(5). 862–867. 282 indexed citations

6.

Tryfonopoulos, Dimitrios, Norma O’Donovan, B. Corkery, Martin Clynes, & John Crown. (2009). Activity of dasatinib with chemotherapy in triple-negative breast cancer cells. Journal of Clinical Oncology. 27(15_suppl). e14605–e14605. 8 indexed citations

7.

Corkery, B., John Crown, Sandra Roche, et al.. (2009). Constitutive Activation of Src Kinase as a Mechanism of Acquired Resistance to Dasatinib in Triple Negative Breast Cancer.. Cancer Research. 69(24_Supplement). 5066–5066. 1 indexed citations

8.

O’Donovan, Norma, B. Corkery, & John Crown. (2008). Targeted treatment of advanced and metastatic breast cancer with lapatinib. OncoTargets and Therapy. 1. 21–21.

9.

Corkery, B., Norma O’Donovan, Martin Clynes, & John Crown. (2007). Epidermal growth factor receptor (EGFR) inhibition in triple-negative breast cancer (BrCa). Journal of Clinical Oncology. 25(18_suppl). 14071–14071. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact